Datavault AI Licenses Technology Exclusively to Wellgistics Health to Disrupt PBM-Driven Drug Pricing

Datavault AI Inc. (NASDAQ: DVLT) has announced an exclusive patent licensing agreement with Wellgistics Health Inc., targeting inefficiencies in prescription drug pricing driven by pharmacy benefit managers (PBMs). The agreement grants Wellgistics Health sole access within its market segment to Datavault AI’s proprietary technologies, including the PharmacyChain platform designed to track and manage prescription fulfillment from manufacturer to patient while automating processes traditionally routed through PBMs.

Prescription drug prices in the United States are among the highest in the world, partly due to complex rebate structures controlled by PBMs. By granting exclusivity, Datavault AI creates a stronger commercial incentive for adoption while reinforcing the value of its intellectual property portfolio. The PharmacyChain platform aims to streamline prescription distribution and reduce reliance on these intermediaries, potentially lowering costs for patients and payers.

According to the company, the agreement outlines an exclusive patent license granted to Wellgistics Health, giving the company sole access within its market segment to Datavault AI’s proprietary technologies. This exclusivity prevents direct competitors from using the same technology, encouraging investment and deployment. The partnership positions Datavault AI’s technology at the center of a platform designed to address pricing inefficiencies in the pharmaceutical supply chain.

The announcement highlights the growing role of artificial intelligence and digital asset infrastructure in healthcare. Datavault AI focuses on AI-driven data monetization and digital asset infrastructure, and this license represents a strategic move into the healthcare sector. For Wellgistics Health, access to exclusive technology could provide a competitive advantage in the prescription fulfillment market.

Industry observers note that PBMs have faced increasing scrutiny for their role in drug pricing. The PharmacyChain platform offers an alternative by automating processes and increasing transparency. Further details on the financial terms of the agreement were not disclosed. The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT.

This development underscores the potential for technology companies to disrupt traditional healthcare intermediaries. By leveraging exclusive licenses, companies like Datavault AI can monetize their intellectual property while enabling partners to innovate in regulated markets. The impact on drug pricing will depend on adoption rates and regulatory responses.